Atezolizumab in Early-Stage Triple-Negative Breast Cancer: NSABP B-59/GeparDouze Trial Results and Biomarker Analysis
- The phase 3 NSABP B-59/GeparDouze trial evaluating atezolizumab combined with neoadjuvant chemotherapy in early-stage triple-negative breast cancer did not meet its primary endpoint of event-free survival, according to...
- Patients with early-stage triple-negative breast cancer received neoadjuvant chemotherapy administered with or without atezolizumab during the randomized phase 3 investigation.
- Despite the overall trial missing its primary endpoint, comprehensive translational analyses conducted alongside the study revealed specific biological determinants of response within the tumor microenvironment.
The phase 3 NSABP B-59/GeparDouze trial evaluating atezolizumab combined with neoadjuvant chemotherapy in early-stage triple-negative breast cancer did not meet its primary endpoint of event-free survival, according to findings published in Nature Medicine on September 1, 2026.
Trial Outcomes and Primary Endpoint Results
Patients with early-stage triple-negative breast cancer received neoadjuvant chemotherapy administered with or without atezolizumab during the randomized phase 3 investigation. Data from the study confirmed that the addition of the immunotherapy agent did not significantly improve event-free survival compared to chemotherapy alone, falling short of the trial’s primary statistical goal.
Tumor Microenvironment Determinants and Biomarker Insights
Despite the overall trial missing its primary endpoint, comprehensive translational analyses conducted alongside the study revealed specific biological determinants of response within the tumor microenvironment. According to the research published in Nature Medicine, basal-like immune-activated tumors demonstrated a potential for responding favorably to the combination of atezolizumab and chemotherapy.
Related reading